JAMA Network
About The Study: This cross-sectional study suggests that despite increasing clearance of artificial intelligence (AI)/machine learning (ML) devices, standardized efficacy, safety, and risk assessment by the Food and Drug Administration (FDA) are lacking. Dedicated regulatory pathways and post-market surveillance of AI/ML safety events may address these challenges.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
